Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
NCT06911112 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
- Lead sponsor
- Neurocrine Biosciences
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- March 31, 2025
- Completion date
- July 31, 2027
- Enrollment
- 200 (estimated)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.